Sanjiv J Shah1, Mardi Gomberg-Maitland2, Thenappan Thenappan2, Stuart Rich3. 1. Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL. 2. Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL. 3. Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL. Electronic address: srich@medicine.bsd.uchicago.edu.
Abstract
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) prevent the development of and reverse pulmonary hypertension (PH) in animal models. We sought to determine whether SSRIs are associated with a decreased incidence of PH in at-risk patients and whether SSRIs are associated with decreased mortality in patients with established PH. METHODS: In a case-control study of patients enrolled in the Surveillance of Pulmonary Hypertension in America (SOPHIA) registry, we tested whether patients without PH (no-PH group; n = 155) were more likely to be receiving SSRIs when compared to those with confirmed PH (n = 1,180). In a separate cohort study of adults with documented PH in the referral-based Pulmonary Hypertension Connection (PHC) registry (n = 542), we classified patients into categories by SSRI use, and we examined whether SSRI use was associated with decreased mortality. RESULTS: In SOPHIA, the confirmed PH group was less likely to be receiving SSRIs compared with the no-PH group (univariate odds ratio [OR], 0.56 [95% confidence interval (CI), 0.39 to 0.82]; p = 0.003; multivariate OR, 0.71l [95% CI, 0.48 to 1.06]; p = 0.09). In the PHC, 69 of 542 patients (13%) were receiving SSRIs at the time of referral. During a mean (+/- SD) follow-up period of 4.0 +/- 3.1 years, 12% of patients receiving SSRIs vs 23% of patients not receiving SSRIs died (hazard ratio [HR], 0.35; 95% CI, 0.14 to 0.87; p = 0.023). The association between SSRI use and decreased mortality persisted after adjusting for age, gender, etiology of PH, and obesity (HR, 0.35; 95% CI, 0.14 to 0.88; p = 0.026). CONCLUSIONS: SSRIs appear to be associated with a decreased development of PH and a decreased mortality in PH. These findings provide a rationale for clinical trials of SSRIs in PH.
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) prevent the development of and reverse pulmonary hypertension (PH) in animal models. We sought to determine whether SSRIs are associated with a decreased incidence of PH in at-risk patients and whether SSRIs are associated with decreased mortality in patients with established PH. METHODS: In a case-control study of patients enrolled in the Surveillance of Pulmonary Hypertension in America (SOPHIA) registry, we tested whether patients without PH (no-PH group; n = 155) were more likely to be receiving SSRIs when compared to those with confirmed PH (n = 1,180). In a separate cohort study of adults with documented PH in the referral-based Pulmonary Hypertension Connection (PHC) registry (n = 542), we classified patients into categories by SSRI use, and we examined whether SSRI use was associated with decreased mortality. RESULTS: In SOPHIA, the confirmed PH group was less likely to be receiving SSRIs compared with the no-PH group (univariate odds ratio [OR], 0.56 [95% confidence interval (CI), 0.39 to 0.82]; p = 0.003; multivariate OR, 0.71l [95% CI, 0.48 to 1.06]; p = 0.09). In the PHC, 69 of 542 patients (13%) were receiving SSRIs at the time of referral. During a mean (+/- SD) follow-up period of 4.0 +/- 3.1 years, 12% of patients receiving SSRIs vs 23% of patients not receiving SSRIs died (hazard ratio [HR], 0.35; 95% CI, 0.14 to 0.87; p = 0.023). The association between SSRI use and decreased mortality persisted after adjusting for age, gender, etiology of PH, and obesity (HR, 0.35; 95% CI, 0.14 to 0.88; p = 0.026). CONCLUSIONS: SSRIs appear to be associated with a decreased development of PH and a decreased mortality in PH. These findings provide a rationale for clinical trials of SSRIs in PH.
Authors: Ali Sadoughi; Kari E Roberts; Ioana R Preston; Ginny P Lai; Deborah H McCollister; Harrison W Farber; Nicholas S Hill Journal: Chest Date: 2013-08 Impact factor: 9.410
Authors: Corey E Ventetuolo; R Graham Barr; David A Bluemke; Aditya Jain; Joseph A C Delaney; W Gregory Hundley; Joao A C Lima; Steven M Kawut Journal: PLoS One Date: 2012-02-17 Impact factor: 3.240
Authors: Mike Petrassi; Rob Barber; Celine Be; Sarah Beach; Brian Cox; Anne-Marie D'Souza; Nick Duggan; Martin Hussey; Roy Fox; Peter Hunt; Gabor Jarai; Takatoshi Kosaka; Paul Oakley; Viral Patel; Neil Press; David Rowlands; Clemens Scheufler; Oliver Schmidt; Honnappa Srinivas; Mary Turner; Rob Turner; John Westwick; Alison Wolfreys; Nuzhat Pathan; Simon Watson; Matthew Thomas Journal: Front Pharmacol Date: 2017-05-05 Impact factor: 5.810